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Since World War II, the number of deaths due to cutaneous malig-
nant melanoma (CMM) has increased sharply in most fair-skinned
populations (Armstrong and Kricker, 1994; Swerdlow, 1990).
However, the rate of increase has varied by country (La Vecchia et
al, 1999). For example, up to 1990, the increase in CMM mortality
was found to be 30–50% greater in Southern and Central Europe
than in Northern Europe (Swerdlow, 1990; Balzi et al, 1997).
There is also evidence that CMM mortality rates are plateauing
or beginning to fall in recent generations in the USA and in
Australia (Scotto et al, 1991; Rousch et al, 1992; Giles et al, 1996).
These declines in mortality are, however, restricted to recent birth
cohorts while death rates continue to increase in older generations.
In European countries, in 1990, there was no indication of a
similar phenomenon (Balzi et al, 1997), except in data from
Scotland (1979–1994) which showed a stabilization of mortality in
women (all ages) and in men younger than 65 years old (MacKie
et al, 1997).
Because of the apparently contrasting trends in CMM mortality
in different countries, we decided to investigate whether the
decreases recently observed in Australia and the USA were
emerging elsewhere. Our strategy was to limit our analysis to fair-
skinned populations that possessed long time series and large
annual numbers of CMM deaths. In this way, we attempted to base
our models on the best data available rather than including every
population irrespective of data quality and chance variation.
MATERIALS AND METHODS
CMM mortality data were obtained from the World Health
Organization Cancer Mortality Data Bank. Populations were
selected for analysis that were predominantly Caucasian (except
Japan) and that were of a sufficient size to provide adequate
numbers of events (an average of 100 CMM deaths annually in at
least one sex) over a period of at least 30 years. Germany was
excluded because of missing data in some years for the former
eastern part of the country. The Netherlands was not selected
because of insufficient numbers of deaths. Because of small
numbers, the Nordic countries of Denmark, Finland, Sweden and
Norway were combined. In combining the Scandinavian countries
we did not take into account a priori evidence concerning trends in
these populations. Altogether nine countries or macro-regions had
adequate data available from at least 1960 to 1994 (1992 for Italy,
1991 for Czechoslovakia and 1993 for the USA and the Nordic
countries). The populations we selected are representative of most
of the world regions affected by CMM.
Annual data were obtained for each sex by 5-year age groups.
Rates were age-adjusted to the World Standard Population for the
age groups 30–59 and 60–79. The average annual percentage
increase in rates between 1960 and 1990 was computed for the two
age groups in order to explore the general trends in CMM
mortality in young and old people.
As previously reported (Swerdlow, 1990), there was a
pronounced peak in rates in France in 1968 probably due to
misclassification problems, so for this year French data were inter-
polated from adjacent periods. In the USA, the inclusion of
African-Americans in the denominators and numerators is likely
to have diminished substantially the magnitude of the rates
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the trend patterns.
Variations in mortality rates can reflect the combined effects of
birth cohort, period and age; the most effective and reliable way to
examine their respective influences is via age–period–cohort
(APC) models. Such models yield a meaningful estimate of the
‘drift’ – a measure of the linear increase/decrease of mortality
rates over time. Drift is the sum of both linear period and birth
cohort effects. It is impossible to separate unequivocally these two
effects because age, period and cohort of birth are not independent
(Holford, 1983). As a consequence, estimates of mortality rates by
cohort of birth (combination of drift and non-linear effects) vary
according to the attribution of drift to period or to birth cohort. We,
therefore, chose to perform a sensitivity analysis by graphing the
estimates after attributing: (1) the entire drift to a period effect, (2)
the entire drift to a birth cohort effect and (3) half the drift to a
period effect and half to a birth cohort effect. Studies published
almost two decades ago (Lee et al, 1979; Venzon and Moolgavkar,
1984) suggested that the rise in CMM mortality was following a
birth cohort pattern. Hence, the scenario where all the drift is
attributed to a period effect is improbable. In drawing conclusions
from this analysis it should be noted that the most recent genera-
tions contain few deaths and consequently the corresponding rate
estimates have relatively large standard errors.
For the APC models, data were grouped in 5-year periods.
Hence birth cohorts are in 10-year groups with a 5-year overlap
between adjacent groups. In the graphs, birth cohorts are identified
by their middle year. We restricted the age range to 30–84 years in
order to avoid age groups with small numbers of deaths. We
followed the implementation of APC models described by Holford
(1992) using the statistical package S-plus 4.5 (Mathsoft). Further
details of the APC analysis are available on request.
RESULTS
Trends in the age-standardized rates
Age-standardized CMM mortality rates for the 30–59 and 60–79
age groups are shown in Figure 1. Australia and Japan are drawn
to different scales because of the different magnitude of the
mortality rates observed in these countries.
In the age group 30–59, in 1960, CMM mortality rates were low
in all countries, and equivalent in men and women. In France, Italy
and Czechoslovakia, there were fewer than 0.5 deaths due to
CMM per 100 000 annually, while in Australia and the USA, there
were 2 deaths per 100 000 – other countries having intermediate
values. Over the period 1960–1990, in Australia, CMM mortality
in the 30–59 age group increased annually by an average 2% in
men, while it remained almost stable in women. A similar pattern
was observed in the USA, with an average annual increase of 2%
in men and of 1% in women. The highest rates of increase in
CMM mortality rates were found in France, Italy and
Czechoslovakia, with death rates increasing annually by 9–16%
without any significant sex difference.
In the age group 60–79, increases in CMM mortality rates were
greater than in the 30–59 age group, and the most dramatic
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Figure 1 Age-adjusted mortality rates for young (30–59) and old (60–79) men and women (world standard population)increases were observed among men. The annual percentage
increase in rates for men and women 60–79 years old was, respec-
tively, 12% and 4% in Australia, 7% and 2% in the USA, and 9%
and 4% in the Nordic countries. We found a less marked difference
between men and women in the CMM mortality increase in
Canada (6% for men and 4% for women), Japan (6% and 4%) and
the UK (7% and 5%). In France, Italy and Czechoslovakia, CMM
mortality rates were low in the 1960s, but afterwards, average
annual increases were 24% and 27% in French men and women,
15% and 13% in Italian men and women, and 17% and 33% in
Czechoslovakian men and women. Because CMM mortality
increased more in older than in younger people, those who died
from CMM in 1994 were 10 years older on average than those who
died in 1960.
Age–period–cohort models
The age–period–cohort models yielded drift terms (measures of
the average trend over time) that were all positive and in agree-
ment with the annual percentage increases described above. CMM
mortality rose linearly during the period of observation in every
population. In every country but Japan, the increase was greater
(higher drift) for men than for women. The largest sex differences
in drift were observed in Australia, Canada and the USA.
Consistent with the analysis of the age-standardized rates, the
highest values for drift were found in France, Italy and
Czechoslovakia.
Trends in mortality rates by birth cohort have been derived from
the APC model, and are shown in Figure 2 for three selected coun-
tries (Australia, UK and France). These countries were chosen
because they represented the three CMM mortality patterns that
we observed after APC modelling (see below). Each graph
contains three plots that described different scenarios: in the upper
plot, all the drift is attributed to a birth cohort effect, in the lower
plot all the drift is attributed to a period effect. The rates displayed
in Figure 2 simply reflect the trend in rates by birth cohort and are
therefore not comparable with actual rates observed in popula-
tions. If in each scenario rates are decreasing, we can conclude that
there is a real decrease. The trends in CMM mortality rates
illustrated by these models describe three patterns:
1. increasing rates until generations born around 1930–1935
(for Australia increasing rates ceased earlier), followed by
decreasing rates in more recent birth cohorts (in Australia,
the Nordic countries and the USA)
2. increasing rates until generations born during World War II,
followed by flattening or slightly decreasing rates in more
recent birth cohorts (UK, Canada)
3. a steep, almost linear, increase with no major change in this
trend (France, Czechoslovakia, and Italy).
CMM mortality rates in Japan showed a pattern similar to that
described in the third group but the rates of increase were much
smaller.
DISCUSSION
We have succeeded in identifying meaningful patterns in the
global CMM epidemic using data only from populations with good
quality death registration and relatively lengthy time series. Our
analysis suggests that populations are at different places on the
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Figure 2 Trends in mortality rates from the age–period–cohort model for men and women in three selected countriesCMM mortality epidemic curve and that they fall into three
distinct groups. In some the mortality trend is still strongly
waxing, in others it is beginning to wane, and in a few, it is
definitely diminishing.
The global increase in CMM mortality among fair-skinned
populations has long been regarded as a consequence of increasing
sun exposure to people sensitive to the harmful effects of sunlight.
Recent decreases in CMM mortality that have been observed in
some populations have been attributed to the success of skin
cancer prevention programmes. This is an attractive assertion that
is difficult either to prove or disprove, though there is some
evidence from Scotland that interventions can achieve changes
associated with reduced mortality (MacKie and Hole, 1992). Most
of these programmes have combined messages of solar protection
with those of early detection, and there is some epidemiological
evidence that reducing sun exposure in childhood reduces CMM
risk (Autier and Doré, 1998), but there is little evidence that 
this is true in adults (English and Milne, 1999). If prevention
programmes are effective in reducing CMM mortality, early
effects should be noticeable in the younger age groups rather than
in the older ones.
On face value, the trend in age at death is encouraging – in
every population the median age at death has increased between
1960 and the early 1990s, people dying from CMM in 1994 being
10 years older on average than those who died in 1960. However,
this is mostly due to the greater increase in CMM mortality rates
among older people compared with younger people. Three mecha-
nisms may have contributed towards this age contrast in CMM
mortality:
1. It is probable that changes towards safer sun exposure habits in
recent decades have been greater in the young. As age is a
marker of lifetime sun exposure, CMM susceptible people
who were 60–79 years old in 1994 experienced a lifetime sun
exposure higher than similar people of the same age in 1960.
Given the importance of sun exposure during childhood to
CMM in adult life (Autier and Doré, 1998), the continuously
increasing CMM mortality observed among older people could
be the consequence of heavy sun exposure when they were
young
2. The decreasing thickness of CMM, reported in several
countries, has been more pronounced in younger people
(Van der Spek-Keijser et al, 1997; Bucchi et al, 1992)
3. The improvement in survival from CMM does not seem to be
entirely attributable to earlier stage at diagnosis or to better
medical management (Masbach et al, 1994). It is possible that
the disease of ‘CMM’ has decreased in aggressiveness. Recent
epidemiological data (Autier and Doré, 1998; Burton and
Armstrong, 1994) suggest that changes in CMM behaviour
could result from variations in the amounts of sun exposure
experienced during different periods of life.
The increase in mortality has often been greater for men than for
women. CMM is known to have a worse prognosis in men
(MacKie et al, 1992; Thörn et al., 1994; Smith et al., 1998). Some
data also show a sex difference in effectiveness of CMM preven-
tion campaigns. For example, in Scotland, campaigns resulted in
higher proportions of thin CMMs in women than in men (MacKie
and Hole, 1992). The effects on mortality induced by a sex differ-
ence in CMM awareness would be amplified by the sex difference
in anatomic distribution. In men, CMM arises more often on the
back and on the head and neck where CMMs carry a poorer prog-
nosis than those detected at other sites. In women, the increase in
CMM incidence has been greater on the legs, where it has a better
prognosis and is easier to detect by self-examination.
Is the end of the increasing trend in sight?
The three patterns in CMM mortality that we have described
correlate with time differences in the initiation of large-scale skin
cancer prevention programmes encouraging sun protection and
surveillance of pigmented skin lesions. The medical literature
indicates that these did not start at the same time in all countries:
in some Australian states, prevention programmes started in the
1960s (Giles et al, 1996) and then national programmes (‘Slip,
Slop, Slap’ and ‘Sun Smart’) followed in the 1980s. In the USA,
Canada, UK and Sweden, national programmes started in the
1980s or early 1990s (Robinson et al, 1997; Rivers and Gallagher,
1995; Melia, 1995; Möller et al., 1997). In France, Italy and
Czechoslovakia, however, we found no report on organized 
long-term national programmes. Other reports suggest that the
latter situation pertains to most Southern and Central European
countries (La Vecchia et al, 1999; Bleyen et al, 1999).
In the first group of populations the epidemic of CMM mortality
has peaked and, unless population behaviour changes to an
increase in risky exposures, it is likely that further declines in
mortality will be experienced over the coming years. In the second
group the signs are encouraging but further gains may be enhanced
by sustained and increasingly resourced prevention campaigns.
The third group of largely central and southern European countries
are still experiencing an unchecked increase in CMM deaths, and,
in the absence of effective skin cancer prevention programmes,
their CMM mortality can be expected to rise unabated.
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